Novoteris, LLC Announces $2.8 Million Award from Cystic Fibrosis Foundation Therapeutics to Support Development of Inhaled Nitric Oxide Antimicrobial Therapy

Garden Grove, CA– Novoteris, LLC announced today a $2.8 million agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to develop an inhaled nitric oxide antimicrobial therapy for people with cystic fibrosis (CF) who have airway bacterial colonization. The Novoteris investigators’ pilot trial in Europe of this therapy reported encouraging microbiological and lung function changes following two weeks of treatment in patients with CF. Gaseous nitric oxide’s potent antimicrobial properties, lack of bacterial resistance, and its small molecule penetration capabilities could provide a promising alternative non-antibiotic approach to treating…

Continue Reading Novoteris, LLC Announces $2.8 Million Award from Cystic Fibrosis Foundation Therapeutics to Support Development of Inhaled Nitric Oxide Antimicrobial Therapy